FDA GRANTS MERCK'S EMEND ADDITIONAL APPROVAL
Merck has announced that the FDA gave additional approval to its Emend nausea treatment for sickness that occurs after surgery.
In January, the FDA approved Emend for use with other nausea treatments for cancer patients with the nausea and vomiting associated with chemotherapy.
The new approval allows Emend to be given as a treatment for the prevention of postoperative nausea and vomiting, one of the most common side effects following surgery.
For the post-surgery use, Merck submitted data from two clinical trials testing 40 mg of Emend against 4 mg of intravenous Zofran, made by GlaxoSmithKline.